Alacris Investment Gives Qiagen Access to Modeling Tool for Cancer Biomarker Discovery
January 21, 2011
Alacris Investment Gives Qiagen Access to Modeling Tool for Cancer Biomarker Discovery
ModCell uses a patient's normal genomic data as well as the genomic and transcriptomic profiles of the patient's tumor to generate object-oriented models that can be used to personalize cancer treatments.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Qiagen Touts SABiosciences' Bioinformatics Prowess as Key to Biomarker Discovery
August 13, 2010 / BioInform - Qiagen Buys Genomic Data Analysis Firm Ingenuity Systems for $105M
April 30, 2013 / GenomeWeb Daily News - Alacris, GSK Ink Cancer Drug Stratification Deal
November 14, 2012 / GenomeWeb Daily News - Qiagen Partners with SAP to Develop Informatics for Sequence Assembly, Variant Identification
July 6, 2012 / BioInform - Case Western Spinoff NeoProteomics Bags $300K Grant, Finalizes Licensing Deal with University
September 2, 2011 / BioInform